Evidence map›Paper›PMID 30304338›Full record

Trial reportJAMA surgery2019

Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.

Rutger C H Stijns, Eelco J R de Graaf, Cornelis J A Punt, Iris D Nagtegaal, Joost J M E Nuyttens, Esther van Meerten, Pieter J Tanis, Ignace H J T de Hingh, George P van der Schelling, Yair Acherman and 8 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in JAMA surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 8 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient data.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020
    Pooled it
  8. Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 1 country.

Rutger C H StijnsDepartment of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.
Eelco J R de GraafDepartment of Surgery, IJsselland Hospital, Capelle aan de Ijssel, the Netherlands.
Cornelis J A PuntDepartment of Medical Oncology, Academic Medical Centre, Amsterdam, the Netherlands.
Iris D NagtegaalDepartment of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Joost J M E NuyttensDepartment of Radiation Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Esther van MeertenDepartment of Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.
Pieter J TanisDepartment of Surgery, Academic Medical Centre, Amsterdam, the Netherlands.
Ignace H J T de HinghDepartment of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
George P van der SchellingDepartment of Surgery, Amphia Hospital, Breda, the Netherlands.
Yair AchermanDepartment of Surgery, Medical Centre Slotervaart, Amsterdam, the Netherlands.
Jeroen W A LeijtensDepartment of Surgery, Laurentius Hospital, Roermond, the Netherlands.
Andreas J A BremersDepartment of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.
Geerard L BeetsDepartment of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Christiaan HoffDepartment of Surgery, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
Cornelis VerhoefDepartment of Surgical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Corrie A M MarijnenDepartment of Radiotherapy, Leiden University Medical Centre, Leiden, the Netherlands.
Johannes H W de WiltDepartment of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.
CARTS Study Group
Radboud University Medical Center · NLAcademic Medical Center · NLErasmus University Rotterdam · NLAmphia Ziekenhuis · NLCatharina Ziekenhuis · NLErasmus MC Cancer Institute · NLIJsselland Ziekenhuis · NLLaurentius Ziekenhuis · NLLeiden University · NLMedisch Centrum Leeuwarden · NLRadboud University Nijmegen · NLSlotervaartziekenhuis · NLThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Treatment of rectal cancer is shifting toward organ preservation aiming to reduce surgery-related morbidity. Short-term outcomes of organ-preserving strategies are promising, but long-term outcomes are scarce in the literature. Objective: To explore long-term oncological outcomes and health-related quality of life (HRQL) in patients with cT1-3N0M0 rectal cancer who underwent neoadjuvant chemoradiotherapy (CRT) followed by transanal endoscopic microsurgery (TEM). Design, Setting, and Participants: In this multicenter phase II feasibility study, patients with cT1-3N0M0 rectal cancer admitted to referral centers for rectal cancer throughout the Netherlands between February 2011 and September 2012 were prospectively included. These patients were to be treated with neoadjuvant CRT followed by TEM in case of good response. An intensive follow-up scheme was used to detect local recurrences and/or distant metastases. Data from validated HRQL questionnaires and low anterior resection syndrome questionnaires were collected. Data were analyzed from February 2011 to April 2017. Main Outcomes and Measures: The primary study outcome of the study was the number of ypT0-1 specimens by performing TEM. Secondary outcome parameters were locoregional recurrences and HRQL. Results: Of the 55 included patients, 30 (55%) were male, and the mean (SD) age was 64 (39-82) years. Patients were followed up for a median (interquartile range) period of 53 (39-57) months. Two patients (4%) died during CRT, 1 (2%) stopped CRT, and 1 (2%) was lost to follow-up. Following CRT, 47 patients (85%) underwent TEM, of whom 35 (74%) were successfully treated with local excision alone. Total mesorectal excision was performed in 16 patients (4 with inadequate responses, 8 with completion after TEM, and 4 with salvage for local recurrence). The actuarial 5-year local recurrence rate was 7.7%, with 5-year disease-free and overall survival rates of 81.6% and 82.8%, respectively. Health-related quality of life during follow-up was equal to baseline, with improved emotional well-being in patients treated with local excision (mean score at baseline, 72.0; 95% CI, 67.1-80.1; mean score at follow-up, 86.9; 95% CI, 79.2-94.7; P = .001). Major, minor, and no low anterior resection syndrome was experienced in 50%, 28%, and 22%, respectively, of patients with successful organ preservation. Conclusions and Relevance: In early-stage rectal cancer (cT1-3N0M0), CRT enables organ preservation with additional TEM surgery in approximately two-thirds of patients with good long-term oncological outcome and HRQL. This multimodality treatment triggers a certain degree of bowel dysfunction, and one-third of patients still undergo radical surgery and are overtreated by CRT.

Indexed as

AdultAgedAged, 80 and overChemoradiotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalFeasibility StudiesFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNetherlandsOrgan Sparing TreatmentsRectal NeoplasmsTransanal Endoscopic Microsurgery

Identifiers

PMID30304338
PMCPMC6439861
OpenAlexW2897913814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.